MRKR
Marker Therapeutics, Inc.Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-03-18 |
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine highlighted promising results of multi-antigen targeted T cells in pancreatic cancer |
| 2026-02-18 |
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its |
| 2026-01-26 |
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology
National broadcast highlights the need for new approaches in one of the deadliest forms of cancer HOUSTON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company with the worldwide exclusive license of Multi-Antigen Targeted T cells |
| 2026-01-05 |
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study Study highlights correlation between the clinical benefit and the expansion and persistence of Multi-Antigen |
| 2025-11-14 |
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in relapsed Non-Hodgkin lymphoma (NHL) patients in the ongoing APOLLO study First patient treated in |
| 2025-11-05 |
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
HOUSTON , Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the |
| 2025-11-03 |
Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data MT-601 demonstrated robust safety profile with no dose limiting toxicities (DLTs) or immune-effector cell associated neurotoxicity syndrome (ICANS ) in the dose |
| 2025-10-06 |
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment OTS product was well tolerated - safety data consistent with other MAR-T cell studies HOUSTON , Oct. |
| 2025-08-28 |
Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
HOUSTON , Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics , Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its |
| 2025-08-26 |
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating complete response (CR) Favorable safety profile observed in study participants with no dose |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-02-25 | Oppenheimer 36th Annual Healthcare Life Sciences Conference | Conference |
| 2025-09-10 | Marker Therapeutics Fireside Chat – H.C. Wainwright Conference | Conference |
| 2025-08-26 | Marker Therapeutics Webcast - APOLLO Data | Webcast |
| 2025-08-12 | Canaccord Genuity 45th Annual Growth Conference – Marker Tx Fireside Chat | Conference |
| 2025-05-28 | KOL Webinar: CAR-T Therapies: After Seven Years, the Results are In, and the Debate Isn’t Over | Event |
| 2025-02-25 | H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference | Conference |
| 2024-12-12 | 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators & Investors Symposium | Event |
| 2024-12-02 | The Citizens JMP Hematology and Oncology Summit | Event |
| 2024-03-26 | H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference Presentation | Conference |
| 2023-09-13 | H.C. Wainwright 25th Annual Global Investment Conference | Conference |